Breakthrough ovarian cancer drug offers patients more time and better quality of life
Summary
A new drug called mirvetuximab soravtansine is now available on the NHS for ovarian cancer patients. This drug targets cancer cells directly, causing fewer side effects and helping patients live longer and feel better than with traditional chemotherapy.Key Facts
- The drug is designed to deliver chemotherapy directly to cancer cells, reducing harm to the rest of the body.
- It is known as a "biological missile" or "Trojan horse" therapy because it uses antibodies to target specific cancer cell markers.
- Mirvetuximab extends average survival time from 12.8 months to 16.5 months for patients with hard-to-treat ovarian cancer.
- About 400 patients a year in England could benefit from this treatment.
- The therapy has fewer side effects, allowing patients to keep their hair and have more energy.
- The drug is given by infusion every three weeks, compared to weekly chemotherapy sessions.
- The National Institute for Health and Care Excellence (NICE) has approved the drug for ovarian, peritoneal, and fallopian tube cancers that have the correct markers and no longer respond to chemotherapy.
- NHS England will fund the treatment, with other UK nations following similar or their own rules.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.